Kevin M. Lalande's most recent trade in Molecular Templates Inc was a trade of 1,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 27, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Sep 2024 | 1,000 | 1,000 | - | - | Stock Option (right to buy) | |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 3,328 | 3,328 | - | - | Stock Option (Right to Buy) | |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 1,154,154 | 1,154,154 | - | - | Warrants (Right to Buy) | |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 402,077 | 402,077 | - | - | Pre-Funded Warrants (Right to Buy) | |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 2.35 per share. | 02 Apr 2024 | 175,000 | 175,000 (0%) | 0% | 2.4 | 411,250 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 3,345 | 3,345 | - | - | Stock Option (Right to Buy) | |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.91 per share. | 13 Jun 2022 | 100,000 | 100,000 (0%) | 0% | 0.9 | 91,000 | Common Stock |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 13 Jun 2022 | 62,000 | 222,000 (0%) | 0% | 0.9 | 55,180 | Common Stock |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.87 per share. | 13 Jun 2022 | 60,000 | 160,000 (0%) | 0% | 0.9 | 52,200 | Common Stock |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 3,431 | 3,431 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 11.11 per share. | 02 Sep 2021 | 10,000 | 720,446 (1%) | 0% | 11.1 | 111,139 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 11.35 per share. | 02 Sep 2021 | 8,100 | 710,446 (1%) | 0% | 11.3 | 91,905 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 11.23 per share. | 02 Sep 2021 | 6,300 | 702,346 (1%) | 0% | 11.2 | 70,739 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 10.52 per share. | 30 Aug 2021 | 8,625 | 685,457 (1%) | 0% | 10.5 | 90,738 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 10.70 per share. | 30 Aug 2021 | 6,000 | 691,457 (1%) | 0% | 10.7 | 64,181 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 10.87 per share. | 30 Aug 2021 | 4,589 | 696,046 (1%) | 0% | 10.9 | 49,892 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 9.87 per share. | 25 Aug 2021 | 14,900 | 666,651 (1%) | 0% | 9.9 | 147,078 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 10.07 per share. | 25 Aug 2021 | 6,200 | 672,851 (1%) | 0% | 10.1 | 62,430 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 10.50 per share. | 25 Aug 2021 | 4,981 | 677,832 (1%) | 0% | 10.5 | 52,282 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 9.58 per share. | 20 Aug 2021 | 37,800 | 640,976 (1%) | 0% | 9.6 | 362,150 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 8.73 per share. | 20 Aug 2021 | 35,679 | 603,176 (1%) | 0% | 8.7 | 311,638 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 9.45 per share. | 20 Aug 2021 | 10,775 | 651,751 (1%) | 0% | 9.5 | 101,871 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 8.73 per share. | 17 Aug 2021 | 28,870 | 547,497 (1%) | 0% | 8.7 | 252,009 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 8.45 per share. | 17 Aug 2021 | 20,000 | 567,497 (1%) | 0% | 8.4 | 168,970 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 8.47 per share. | 17 Aug 2021 | 16,000 | 518,627 (1%) | 0% | 8.5 | 135,446 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 7.86 per share. | 12 Aug 2021 | 31,000 | 471,627 (1%) | 0% | 7.9 | 243,744 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 7.96 per share. | 12 Aug 2021 | 31,000 | 502,627 (1%) | 0% | 8.0 | 246,717 | Common Stock |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Purchase of securities on an exchange or from another person at price $ 7.55 per share. | 12 Aug 2021 | 31,000 | 440,627 (1%) | 0% | 7.5 | 233,932 | Common Stock |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 2,910 | 2,910 | - | - | Stock Option (Right to Buy) | |
| Lumos Pharma Inc | Kevin M. Lalande | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 367 | 1,076 (0%) | 0% | 0 | Common Stock | |
| Molecular Templates Inc | Kevin M. Lalande | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 13.05 per share. | 16 Sep 2020 | 500,000 | 6,097,298 (13%) | 1% | 13.1 | 6,525,000 | Common Stock |